Pfizer Seeks Regulatory Approval Of Covid-19 Vaccine For Young Children

U.S. pharmaceutical giant Pfizer (PFE) is seeking emergency use authorization from the Food and Drug Administration (FDA) for a Covid-19 vaccine to be given to children aged six months to five years old.

Covid-19 vaccines for children younger than age five could be available as soon as the end of February under a plan that would lead to the potential authorization of a two-shot regimen in the coming weeks, according to multiple media reports.

The FDA has reportedly urged Pfizer to submit the emergency use authorization application so that the regulator can begin reviewing the two-shot data on young children.

Pfizer and its German partner BioNTech (BNTX) had earlier said that they expect the latest results from a clinical trial for children under the age of five to be available by April of this year.

Related Stories